Meeder Asset Management Inc Tg Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $8,214 - $15,530	803 New	803 $12,000
Q2 2021 Aug 09, 2021	SELL	$32.5 - $48.96 $83,687 - $126,072	-2,575 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$41.61 - $54.3 $107,145 - $139,822	2,575 New	2,575 $123,000
Q4 2020 Feb 09, 2021	SELL	$25.27 - $54.9 $140,779 - $305,847	-5,571 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$18.49 - $27.24 $4,640 - $6,837	251 Added 4.72%	5,571 $148,000
Q2 2020 Aug 11, 2020	BUY	$8.9 - $21.84 $28,435 - $69,778	3,195 Added 150.35%	5,320 $105,000
Q1 2020 May 15, 2020	BUY	$7.14 - $15.99 $15,172 - $33,978	2,125 New	2,125 $21,000
Q3 2019 Oct 17, 2019	SELL	$5.38 - $8.99 $3,346 - $5,591	-622 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$6.27 - $8.65 $3,899 - $5,380	622 New	622 $5,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.